NCT03081910View on ClinicalTrials.gov

Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen

PHASE1RecruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

November 1, 2017

Primary Completion Date

June 1, 2028

Study Completion Date

September 1, 2040

Conditions
T-cell Acute Lymphoblastic LymphomaT-non-Hodgkin LymphomaT-cell Acute Lymphoblastic Leukemia
Interventions
GENETIC

Autologous CD5.CAR/28zeta CAR T cells

"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"

GENETIC

Allogeneic CD5.CAR/28zeta CAR T cells

"Three dose levels will be evaluated:~Dose level one: 1×10\^7 cells/m2~Dose level two: 5×10\^7 cells/m2~Dose level three: 1×10\^8 cells/m2"

Trial Locations (2)

77030

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Baylor College of Medicine

OTHER